Seroreactivity to Human Papillomavirus Types 16, 18, 31, and 45 Virus‐Like Particles in a Case‐Control Study of Cervical Squamous Intraepithelial Lesions

Wideroff, Louise; Schiffman, Mark; Haderer, P.; Armstrong, A.; Greer, Catherine E.; Manos, M. Michele; Burk, Robert D.; Scott, David; Sherman, Mark E.; Schiller, John T.; Hoover, RN; Tarone, Robert E.; Kirnbauer, Reinhard

doi:10.1086/315055

Cited by 58 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study described by Wideroff et al (1999) seroprevalence for HPV 16 IgG antibody among cases with squamous intraepithelial lesions (SIL) was 51.3% and for the random control group the seroprevalence for HPV 16 was 15.9%. On the other hand, among high-risk populations in Greenland and Denmark, 56.2% of the Greenlander women and 41.1% of the Danish women were found positive for antibody to HPV 16 (Nonnenmacher et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

et al. 2003

View full text Add to dashboard Cite

A retrospective seroepidemiologic study was performed to examine the association between human papillomaviruses (HPV) 16 infection and carcinomas of the oropharynx, the oesophagus, penis and vagina. Sera were selected from the serum bank from the Antoni van Leeuwenhoek Hospital (Netherlands Cancer Institute) and the Slotervaart Hospital in Amsterdam, the Netherlands. Presence of HPV 16 specific antibody was assessed using HPV 16 L1 capsids. Sera positive for HPV 16 capsid antibody were further tested for antibody against HPV 16 E7 peptides. Prevalence of antibody against HPV 16 L1 capsids among both the negative control group without cancer and the negative control group with gastric cancer was 18%, while seroprevalence among the control group of patients with HPV-associated cervical squamous cell carcinoma was 47% (Po0.001). Among the patients with penile squamous cell carcinoma seroprevalence was 38% (Po0.001), among patients with oropharyngeal carcinoma 33% (P ¼ 0.04) and among patients with oesophageal squamous cell carcinoma 14% (P ¼ 0.7). The serological evidence for association between HPV 16 infection and both oropharyngeal carcinoma and penile carcinoma was established. The conclusion that no association was found between the presence of antibody against HPV 16 L1 capsids and oesophageal squamous cell carcinoma was in accordance with results of other studies carried out in the Netherlands using HPV DNA technology. In the subjects with HPV 16 L1 capsid antibody, no association was found between the antibody against HPV 16 E7 and clinical outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

et al. 2003

View full text Add to dashboard Cite

show abstract

“…4 Type-restricted serologic assays for different HPV types using virus-like particles were first developed in the mid-1990s, 5 and were subsequently shown to be relatively specific for each HPV type. 6 Seroreactivity to HPV 16 is a strong marker of continuous past exposure to HPV 16 and is associated with squamous intraepithelial lesions of the uterine cervix. 6,7 So far 5 seroepidemiological studies, 2 prospective 8,9 and 3 retrospective (casecontrol), [10][11][12] have examined the association of anti-HPV 16 IgG antibodies with the risk of ESCC.…”

mentioning

confidence: 99%

“…6 Seroreactivity to HPV 16 is a strong marker of continuous past exposure to HPV 16 and is associated with squamous intraepithelial lesions of the uterine cervix. 6,7 So far 5 seroepidemiological studies, 2 prospective 8,9 and 3 retrospective (casecontrol), [10][11][12] have examined the association of anti-HPV 16 IgG antibodies with the risk of ESCC. Both prospective studies found a strong positive association between HPV 16 and ESCC.…”

mentioning

confidence: 99%

Human papillomavirus serology and the risk of esophageal and gastric cancers: Results from a cohort in a high‐risk region in China

Kamangar

Qiao

Schiller

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Each year, esophageal and gastric cancers cause more than 900,000 deaths worldwide. Human papilloma virus (HPV), especially type 16, has been suggested to have a role in the etiology of esophageal cancer, however, the results of previous seroepidemiological studies have not been consistent. We conducted a large prospective study to examine the association between serum antibodies to HPV 16, HPV 18 and HPV 73 and subsequent development of esophageal squamous cell carcinoma (ESCC), gastric cardia adenocarcinoma (GCA), and gastric noncardia adenocarcinoma (GNCA) in a high-risk population for these cancers in Linxian, China. Case and control subjects for this study were selected from the 29,584 participants of the Linxian General Population Trial. Prediagnostic serum samples from 99 cases of ESCC, 100 cases of GCA, 70 cases of GNCA, and 381 age-and sex-matched controls were selected for this study. The presence of antibodies to HPV virus-like particles was determined by type-specific enzyme-linked immunosorbent assays. Fewer than 15% of ESCC, GCA, or GNCA cases were positive for each HPV type, and no significant associations were found. The adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for HPV 16 seropositivity and ESCC, GCA, and GNCA risk were 1.6 (0.8-3.3), 1.3 (0.6-2.8) and 0.4 (0.1-1.6), respectively. The comparable ORs (95% CIs) for HPV 18 were 1.0 (0.4-2.2), 0.9 (0.4-2.1) and 1.5 (0.6-3.4). For HPV 73, these figures were 1.3 (0.6-2.5), 1.2 (0.6-2.3) and 0.9 (0.4-2.1). The results of this study do not support a major role for HPV 16, HPV 18 and HPV 73 in the etiology of esophageal and gastric cancers in Linxian, China. ' 2006 Wiley-Liss, Inc.Key words: esophageal cancer; human papillomavirus; serology Oncogenic types of human papillomavirus (HPV), most notably HPV 16 and HPV 18, are recognized as the most significant risk factors for cervical cancer. 1 The role of HPV in the etiology of cancers of vulva, anus, penis and oropharyngeal cavity has also been established. 2 The role of HPV in the etiology of esophageal cancer, however, remains controversial. Syrjanen first suggested a role for HPV in the etiology of esophageal squamous cell carcinoma (ESCC) in 1982, based on observing characteristic histological findings suggesting the presence of HPV in benign esophageal epithelia and malignant esophageal tumors. 3 During the past 20 years, several studies have used a variety of techniques, including detection of HPV DNA in esophageal tumor tissues and serologic methods, to examine the association between exposure to HPV and risk of ESCC. 4 The results of HPV DNA studies have not been consistent: case series using polymerase chain reaction (PCR) have found evidence for the presence of HPV in the tumor tissues varying from 0 to 67%. 4 Type-restricted serologic assays for different HPV types using virus-like particles were first developed in the mid-1990s, 5 and were subsequently shown to be relatively specific for each HPV type. 6 Seroreactivity to HPV 16 is a strong marker of continuous past exp...

show abstract

“…Moreover, not all women infected with HPV seroconvert; only about half of all HPV DNA-positive women test positive for corresponding type-specific antibodies using available assays (Kirnbauer et al, 1994;Le Cann et al, 1995). For those women who have seroconverted, however, detection of serum antibodies to HPV capsids is a valid marker of current and past type-specific HPV exposure (Wideroff et al, 1995(Wideroff et al, , 1999Carter et al, 1996;Sasagawa et al, 1998;Touze et al, 2001).We previously reported population-based seroprevalence of HPV-16, -18, -31, and -45 in our 10 000 women population-based study in Costa Rica at enrolment; we confirmed the waning detection of HPV antibodies with age and the determinants of seroprevalence to include increasing lifetime number of sexual partners and smoking (Wang et al, 2003), as similarly reported in other prevalence studies (Stone et al, 2002;Nonnenmacher et al, 2003).To extend our cross-sectional findings, we have now completed HPV-16 serology measurements at a second time point, after 5 -7 years of follow-up. Human papillomavirus 16 was selected because it accounts for the majority of cervical cancers worldwide (Munoz et al, 2003) and is the focus of immunology and vaccinology research (Lowy and Frazer, 2003).…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica

et al. 2004

View full text Add to dashboard Cite

Determinants of human papillomavirus (HPV)-16 serological conversion and persistence were assessed in a population-based cohort of 10 049 women in Guanacaste, Costa Rica. Serologic responses to HPV-16 were measured in 7986 women by VLP-based enzymelinked immunosorbent assay at both study enrolment (1993/94) and at 5 -7 years of follow-up. Seropositive women were defined as X5 standard deviations above the mean optical density obtained for studied virgins at enrolment (n ¼ 573). Seroconnversion (n ¼ 409), persistence (n ¼ 675), and clearance (n ¼ 541) were defined based on enrolment and follow-up serology measurements. Age-specific distributions revealed that HPV-16 seroconversion was highest among 18-to 24-year-old women, steadily declining with age; HPV-16 seropersistence was lowest in women 65 þ years. In age-adjusted multivariate logistic regression models, a 10-fold risk increase for HPV-16 seroconversion was associated with HPV-16 DNA detection at enrolment and follow-up; two-fold risk of seroconversion to HPV-16 was associated with increased numbers of lifetime and recent sexual partners and smoking status. Determinants of HPV-16 seropersistence included a 1.5-fold risk increase associated with having one sexual partner during follow-up, former oral contraceptive use, and a 3-fold risk increase associated with HPV-16 DNA detection at both enrolment and follow-up. Higher HPV-16 viral load at enrolment was associated with seroconversion, and higher antibody titres at enrolment were associated with seropersistence. (Ho et al, 1995). Moreover, not all women infected with HPV seroconvert; only about half of all HPV DNA-positive women test positive for corresponding type-specific antibodies using available assays (Kirnbauer et al, 1994;Le Cann et al, 1995). For those women who have seroconverted, however, detection of serum antibodies to HPV capsids is a valid marker of current and past type-specific HPV exposure (Wideroff et al, 1995(Wideroff et al, , 1999Carter et al, 1996;Sasagawa et al, 1998;Touze et al, 2001).We previously reported population-based seroprevalence of HPV-16, -18, -31, and -45 in our 10 000 women population-based study in Costa Rica at enrolment; we confirmed the waning detection of HPV antibodies with age and the determinants of seroprevalence to include increasing lifetime number of sexual partners and smoking (Wang et al, 2003), as similarly reported in other prevalence studies (Stone et al, 2002;Nonnenmacher et al, 2003).To extend our cross-sectional findings, we have now completed HPV-16 serology measurements at a second time point, after 5 -7 years of follow-up. Human papillomavirus 16 was selected because it accounts for the majority of cervical cancers worldwide (Munoz et al, 2003) and is the focus of immunology and vaccinology research (Lowy and Frazer, 2003). To further our understanding of HPV serology in the natural history of cervical cancer, we report here the epidemiologic characteristics and determinants of HPV-16 serologic conversion and persistence in our Guanacaste, Costa ...

show abstract

Seroreactivity to Human Papillomavirus Types 16, 18, 31, and 45 Virus‐Like Particles in a Case‐Control Study of Cervical Squamous Intraepithelial Lesions

Cited by 58 publications

References 21 publications

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

Human papillomavirus serology and the risk of esophageal and gastric cancers: Results from a cohort in a high‐risk region in China

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica

Contact Info

Product

Resources

About